Drugs and patents in ATC class N06AF - Monoamine oxidase inhibitors, non-selective

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
MARPLAN	isocarboxazid
NARDIL	phenelzine sulfate
PHENELZINE SULFATE	phenelzine sulfate
PARNATE	tranylcypromine sulfate
TRANYLCYPROMINE SULFATE	tranylcypromine sulfate
>Tradename	>Generic Name

Last updated: July 29, 2026

Executive summary: The ATC N06AF “monoamine oxidase inhibitors, non-selective” market is dominated by off-patent, long-established small molecules (notably tranylcypromine and phenelzine). Patent exclusivity in major markets has largely expired, with current barriers shifting from primary drug patents to line extensions such as formulations, manufacturing, specific polymorphs/solid forms, and method-of-use. Competitive pressure is sustained by generic availability and low differentiation, while clinical and regulatory programs are relatively limited due to narrow utilization, safety/tolerability constraints, and diet–drug interaction requirements. The patent estate is therefore fragmented and often does not block entry for conventional oral generics, but may affect entry timing for specific strengths, dosage forms, and controlled-release or alternative solid-form variants where such patents exist.

Because the topic is broad at the ATC class level, the key business implication is that “class-level exclusivity” is not a reliable barrier signal. You must assess patent protection product-by-product (active ingredient and dosage form), then map likely generic entry risks based on Orange Book (US) and equivalent national registers (EP, UK, DE, FR, IT, ES), plus any ongoing Hatch-Waxman litigation or EU SPC status.

Which drugs are in ATC N06AF and who sells them?

Featured snippet answer: ATC N06AF covers non-selective monoamine oxidase (MAO) inhibitors used mainly in depressive disorders: phenelzine and tranylcypromine are the core actives in most formularies and commercial lineups; other legacy agents may appear depending on country indexing.

Phenelzine vs tranylcypromine: commercial reality

Phenelzine: historically established oral therapy; limited share outside specialist use markets due to interaction and dietary restrictions.
Tranylcypromine: similarly legacy, with safety monitoring requirements and diet–drug interactions.

Market dynamic: For both actives, pricing and availability are driven by generic penetration and payer formularies rather than by patent-driven brand differentiation. In major markets, the competitive structure is typically “generic-first” with minimal brand premium.

Switching and formulary behavior

Payer controls: restricted access or prior authorization in many systems where safer alternatives (SSRIs/SNRIs/atypicals) are favored.
Clinical substitution: often constrained by tolerability, prior response, and washout complexity (MAOI dietary and washout protocols).

What patents protect phenelzine and tranylcypromine in the US Orange Book?

Featured snippet answer: For legacy MAOIs, the Orange Book typically shows few (or no) currently active drug-substance or method-of-use patents for phenelzine and tranylcypromine in the US; any remaining listings usually relate to specific formulations, packaging, or narrow method-of-use claims for particular dosing regimens.

How to read the patent estate for N06AF generics

Business-relevant pattern in the class:

Drug substance patents: expired decades ago in most jurisdictions.
Formulation patents: sporadic, often covering specific excipient systems, granulation processes, or solid-state forms.
Method-of-use patents: may exist but tend to be narrow and hard to enforce against label-limited generic substitution.
Orphan/Special designations: uncommon for this class and not a reliable driver of exclusivity.

Generic entry risk mapping (US)

Low barrier for conventional immediate-release oral tablets where no active formulation patent covers that exact strength/dosage form.
Moderate barrier for:
- alternative solid forms (polymorph/co-crystal),
- extended-release or fast-dissolve variants,
- manufacturing/process claims that generics must navigate to avoid literal infringement.

Key business action: For any target active ingredient, map Orange Book “listed drug” to each NDC, then correlate patent claims to the generics’ intended formulation and manufacturing route.

When does non-selective MAOI exclusivity lose protection? (timelines by protection type)

Featured snippet answer: For ATC N06AF, practical exclusivity is usually driven by old drug-substance expiration plus any later formulation/SPC-style protections in specific jurisdictions. In the US, market exclusivity (Hatch-Waxman 5-year/3-year exclusivities) is generally irrelevant for legacy MAOIs because they predate modern exclusivity frameworks; patents are the main gating factor.

Protection timelines that matter for market entry

US patent expiration (20 years from earliest non-provisional priority)
- For legacy MAOIs, this is long past.
US regulatory exclusivity
- Typically absent for legacy generics.
EU Supplementary Protection Certificates (SPCs)
- Can extend protection where a valid basic patent and marketing authorization exist; relevance depends on whether there were qualifying late patents for the actives.
Formulation/polymorph line extensions
- These can extend “effective exclusivity” by months to a few years, not the decade-scale protection seen for novel drugs.

Business implication for R&D and licensing

Licensing focus should be on:
- incremental formulation patents with plausible enforceability,
- compatible manufacturing processes that can be defended without requiring proprietary API chemistry.

Which companies hold the strongest remaining patent estate for N06AF?

Featured snippet answer: The strongest remaining patent estates, where they exist, tend to be held by companies that pursued line-extension work (formulations, solid state, or alternative dosing methods). For core actives, major originators’ primary drug-substance patents have typically expired, shifting the “strongest estate” question to the most recent filings around specific dosage forms and manufacturing methods.

Estate dynamics by claim type

Formulation solid-state: strongest when claims tie to a specific polymorph and are supported by reproducible characterization.
Manufacturing/process: strongest when claimed steps are integral and cannot be designed around cheaply.
Method-of-use: weakest against generics unless the claim aligns with enforceable label language and generic certification triggers it.

What patent litigation affects phenelzine and tranylcypromine generics (Paragraph IV and beyond)?

Featured snippet answer: N06AF generics generally face fewer high-profile Paragraph IV suits than newer CNS assets because most drug-substance and core method claims have expired. Where litigation occurs, it typically targets:

formulation patents for a specific listed drug/NDC,
process or solid-state claims,
narrower use claims tied to label language.

Litigation pattern investors should look for

Hatch-Waxman: Paragraph IV filings against Orange Book listed patents.
FOIAed correspondence and settlement terms: often indicate whether the case turned on formulation equivalence or claim scope.

Business action: Litigation intelligence should be paired with the generics’ ANDA paragraphs (e.g., “no patent” vs “carve-out” vs “non-infringement”) and with product composition (excipients, coating system, dissolution profile).

What formulations are protected by patents for non-selective MAOIs?

Featured snippet answer: When formulation patents exist in N06AF, they most often cover:

specific excipient blends for stability and dissolution,
tablet coating and disintegration behavior,
solid-state attributes such as polymorph control or particle size,
manufacturing steps that ensure uniformity and reduce impurity profiles.

Typical claim features that matter for enforcement

A claim written to a specific polymorph identity or preparation method.
A claim that requires particular dissolution specifications that are hard to meet without matching the patentee’s formulation.

Generic design-around feasibility

High feasibility: if claims cover broad composition categories or generic-equivalent manufacturing steps.
Lower feasibility: if the patent is narrow to a particular solid form and validated with strong analytical data.

How does ATC N06AF compare with other CNS antidepressants in patent and entry barriers?

Featured snippet answer: Compared with newer CNS antidepressant classes (SSRIs/SNRIs/atypicals) that can have sizeable patent families and lifecycle management, N06AF has:

older active ingredients,
minimal active primary patents,
entry largely determined by safety labeling and generic manufacturing rather than IP.

Competitive landscape

Broader CNS therapy: most commercial share has shifted to newer mechanisms.
MAOI positioning: niche and formularies often restrict use, but generics can still capture volume where clinicians choose MAOIs.

What generic entry risks exist for N06AF oral tablets and what could block them?

Featured snippet answer: For N06AF, the generic entry risk is usually low for conventional immediate-release tablets at standard strengths, unless a still-active formulation or solid-state patent covers the exact dosage form and composition used by the target ANDA applicant.

Entry blockers

Active Orange Book patents tied to:
- the exact listed drug,
- specific strengths (not always all strengths).
Active patents on solid forms used in the ANDA manufacture.
Pending injunctions or settlement carve-outs that delay launch.

Entry accelerants

Launch of generics that do not match protected formulation variants.
Design-around solid-state or process differences.
Weak method-of-use enforceability where claims do not align with label and generic certification.

How does biosimilar risk apply to ATC N06AF?

Featured snippet answer: Biosimilar risk is not applicable to ATC N06AF because these are small-molecule MAO inhibitors, not biologics.

Regulatory status: what FDA pathway issues matter for generics of non-selective MAOIs?

Featured snippet answer: Generic entry is typically through ANDAs with bioequivalence to the reference listed drug. The regulatory burden is standard for small molecules: chemistry, manufacturing, controls, and bioequivalence. IP often dictates exclusivity more than regulatory pathway.

Practical compliance focus for generics

Dissolution equivalence for immediate-release tablets.
Impurity profiling and stability, because MAOIs can have tight impurity control requirements.
Labeling and prescribing instructions around diet and drug interactions (this affects clinical uptake and payer acceptance more than regulatory approval alone).

Which jurisdictions can still extend exclusivity for N06AF? (SPC, national patents, MPAs)

Featured snippet answer: The jurisdictions where “effective exclusivity” could still persist for N06AF are the ones where formulation line extensions or SPCs were obtained for relevant basic patents. For legacy MAOIs, this is typically modest and product-specific.

European market dynamic

EU SPCs can extend protection if the qualifying basic patent and marketing authorization align.
National patents can cover:
- specific formulations,
- manufacturing methods,
- solid-state forms.

UK and DE/FR/ES/IT enforcement environment

If formulation patents exist, enforcement strength varies with:
- claim construction,
- local injunction practice,
- venue strategy.

Business implication: Country-by-country freedom-to-operate (FTO) is essential for any planned manufacturing or product relaunch, especially if targeting specific strengths that may align with active formulation listings.

What is the business outlook for ATC N06AF in 2026?

Featured snippet answer: Demand is stable-to-declining in many markets due to preference for newer antidepressants, but N06AF can retain niche utilization. IP-driven growth is limited. Value creation more often comes from:

ensuring supply and bioequivalence,
managing pricing in generic competitions,
differentiating via acceptable safety handling (not novel mechanisms).

Key commercial drivers

Payer restrictions and prior authorization criteria.
Clinician familiarity and patient response history.
Competitive pricing under generic substitution rules.
Supply reliability and manufacturing scalability for API and tablet production.

Key Takeaways

ATC N06AF “non-selective MAO inhibitors” is a legacy small-molecule space where primary drug-substance exclusivity is largely expired.
Market dynamics are dominated by generic penetration, formulary controls, and niche clinical use rather than by active, broad IP barriers.
The practical patent landscape is fragmented and mostly formulation/process/solid-state oriented; generic entry risk is typically low for standard immediate-release tablets unless a still-active Orange Book (or EU/National) listing aligns to the exact NDC/strength and manufacturing approach.
Biosimilar risk is not applicable.
Business value creation is more likely in lifecycle management, product supply, and targeted FTO for specific strengths and dosage forms than in new mechanism discovery.

FAQs

1) Are phenelzine and tranylcypromine still protected by patents in the US?
Legacy drug-substance patents are generally expired; any remaining protection is usually limited to formulation, solid-state, or method-of-use patents tied to specific listed drugs and strengths.

2) What would a Paragraph IV ANDA filing indicate for N06AF?
It typically signals that an ANDA applicant challenges a still-listed Orange Book patent, most often a formulation or method claim rather than a basic drug-substance claim.

3) Can generics be blocked even if the active ingredient patent is expired?
Yes. A still-valid formulation, solid-state, or process patent can block launch for a specific listed drug/NDC strength.

4) Do EU SPCs materially extend protection for non-selective MAO inhibitors?
Only in product-specific circumstances where SPC-qualifying basic patents and marketing authorizations exist; otherwise, the effect is minimal.

5) What is the biggest non-IP barrier to adoption for N06AF generics?
Prescribing behavior and label-driven diet and drug interaction management, which affects uptake even after regulatory approval.

References (APA)

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
European Medicines Agency. (n.d.). European public assessment reports and EPAR information. EMA. https://www.ema.europa.eu/
World Intellectual Property Organization. (n.d.). Patent basics and timelines. WIPO. https://www.wipo.int/
European Patent Office. (n.d.). Supplementary Protection Certificates (SPC) overview. EPO. https://www.epo.org/

Drugs in ATC Class N06AF

Drugs in ATC Class: N06AF - Monoamine oxidase inhibitors, non-selective

ATC N06AF Non-Selective Monoamine Oxidase Inhibitors: market dynamics and patent landscape (2026)